Host sphingolipid biosynthesis is a promising therapeutic target for the inhibition of hepatitis B virus replication

Journal of Medical Virology

Volumn 83, Issue 4, 2011, Pages 587-593

  Tatematsu, Kanako ^a   Tanaka, Yasuhito ^a   Sugiyama, Masaya ^a   Sudoh, Masayuki ^b   Mizokami, Masashi ^a,c  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

HBV; IFN; Lipid raft; Myriocin; SPT inhibitor

Indexed keywords

ALPHA2B INTERFERON; CORE PROTEIN; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON; SPHINGOLIPID; THERMOZYMOCIDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG DOSE REDUCTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LIPOGENESIS; LIVER TOXICITY; MOUSE; NONHUMAN; SUPERNATANT; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DISEASE MODELS, ANIMAL; DNA, VIRAL; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; INHIBITORY CONCENTRATION 50; INTERFERONS; MICE; SPHINGOLIPIDS; TREATMENT OUTCOME; VIRUS REPLICATION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; MUS;

EID: 79951526334     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21970     Document Type: Article

References (27)

1. Abe A, Inoue K, Tanaka T, Kato J, Kajiyama N, Kawaguchi R, Tanaka S, Yoshiba M, Kohara M. 1999. Quantitation of hepatitis B virus genomic DNA by real-time detection PCR. J Clin Microbiol 37: 2899-2903.
2. Campbell SM, Crowe SM, Mak J. 2001. Lipid rafts and HIV-1: From viral entry to assembly of progeny virions. J Clin Virol 22: 217-227.
3. Chua PK, Wang RY, Lin MH, Masuda T, Suk FM, Shih C. 2005. Reduced secretion of virions and hepatitis B virus (HBV) surface antigen of a naturally occurring HBV variant correlates with the accumulation of the small S envelope protein in the endoplasmic reticulum and Golgi apparatus. J Virol 79: 13483-13496.
4. Diminsky D, Schirmbeck R, Reimann J, Barenholz Y. 1997. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): Composition, structure and immunogenicity. Vaccine 15: 637-647.
5. Feng X, Heyden NV, Ratner L. 2003. Alpha interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts. J Virol 77: 13389-13395.
6. Fujita T, Inoue K, Yamamoto S, Ikumoto T, Sasaki S, Toyama R, Chiba K, Hoshino Y, Okumoto T. 1994. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot 47: 208-215.
7. Funk A, Mhamdi M, Hohenberg H, Heeren J, Reimer R, Lambert C, Prange R, Sirma H. 2008. Duck hepatitis B virus requires cholesterol for endosomal escape during virus entry. J Virol 82: 10532-10542.
8. Gavilanes F, Gonzalez-Ros JM, Peterson DL. 1982. Structure of hepatitis B surface antigen. Characterization of the lipid components and their association with the viral proteins. J Biol Chem 257: 7770-7777.
9. Kimura T, Rokuhara A, Sakamoto Y, Yagi S, Tanaka E, Kiyosawa K, Maki N. 2002. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 40: 439-445.
10. Kluepfel D, Bagli J, Baker H, Charest MP, Kudelski A. 1972. Myriocin, a new antifungal antibiotic from Myriococcum albomyces. J Antibiot 25: 109-115.
11. Lange Y, Steck TL. 1985. Cholesterol-rich intracellular membranes: A precursor to the plasma membrane. J Biol Chem 260: 15592-15597.
12. Leaphart CL, Dai S, Gribar SC, Richardson W, Ozolek J, Shi XH, Bruns JR, Branca M, Li J, Weisz OA, Sodhi C, Hackam DJ. 2008. Interferon-gamma inhibits enterocyte migration by reversibly displacing connexin43 from lipid rafts. Am J Physiol 295: G559-G569.
13. Liaw YF. 2001. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antiviral Chem Chemother 12: 67-71.
14. Lin YL, Shiao MS, Mettling C, Chou CK. 2003. Cholesterol requirement of hepatitis B surface antigen (HBsAg) secretion. Virology 314: 253-260.
15. Lok AS. 2002. Chronic hepatitis B. N Engl J Med 346: 1682-1683.
16. Miyake Y, Kozutsumi Y, Nakamura S, Fujita T, Kawasaki T. 1995. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun 211: 396-403.
17. Moffett S, Brown DA, Linder ME. 2000. Lipid-dependent targeting of G proteins into rafts. J Biol Chem 275: 2191-2198.
18. Nichols BJ, Kenworthy AK, Polishchuk RS, Lodge R, Roberts TH, Hirschberg K, Phair RD, Lippincott-Schwartz J. 2001. Rapid cycling of lipid raft markers between the cell surface and Golgi complex. J Cell Biol 153: 529-541.
19. Pelkmans L. 2005. Viruses as probes for systems analysis of cellular signalling, cytoskeleton reorganization and endocytosis. Curr Opin Microbiol 8: 331-337.
20. Pralle A, Keller P, Florin EL, Simons K, Horber JK. 2000. Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J Cell Biol 148: 997-1008.
21. Sakamoto H, Okamoto K, Aoki M, Kato H, Katsume A, Ohta A, Tsukuda T, Shimma N, Aoki Y, Arisawa M, Kohara M, Sudoh M. 2005. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol 1: 333-337.
22. Satoh O, Imai H, Yoneyama T, Miyamura T, Utsumi H, Inoue K, Umeda M. 2000. Membrane structure of the hepatitis B virus surface antigen particle. J Biol Chem 127: 543-550.
23. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT. 2009. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis B. Ann Intern Med 150: 104-110.
24. Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, Gish RG, Kramvis A, Shimada T, Izumi N, Kaito M, Miyakawa Y, Mizokami M. 2006. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology (Baltimore, MD) 44: 915-924.
25. Tanaka Y, Hasegawa I, Kato T, Orito E, Hirashima N, Acharya SK, Gish RG, Kramvis A, Kew MC, Yoshihara N, Shrestha SM, Khan M, Miyakawa Y, Mizokami M. 2004. A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology (Baltimore, MD) 40: 747-755.
26. Umehara T, Sudoh M, Yasui F, Matsuda C, Hayashi Y, Chayama K, Kohara M. 2006. Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem Biophys Res Commun 346: 67-73.
27. Yuan TT, Sahu GK, Whitehead WE, Greenberg R, Shih C. 1999. The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen. J Virol 73: 5731-5740.